Trials
2 active
4 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified (IGIV-C 10%)”In the company’s words, NCT07540221 on ClinicalTrials.gov
- Tested for
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy), Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Main trialPhase 3
- “The main goal of the study is to find out whether XEMBIFY, given once a week under the skin, provides similar levels of immunoglobulin G in the blood over time as Gamunex-C, which is given into a vein once every 3 weeks in people with CIDP. Participants with CIDP will first have up to 28 days of screening to make sure they can join the study. Those who qualify will then start a 19-week treatment period with Gamunex-C. During this period, they will receive Gamunex-C through a vein once every 3 weeks, for a total of 7 doses. Approximately, one week after their last Gamunex-C dose, they will…”In the company’s words, NCT07540221 on ClinicalTrials.gov
- Other names
- IVIG-C · IGIV-C
Other drugs for CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- NipocalimabJohnson & Johnson (Janssen) · Phase 2/3
- RiliprubartSanofi · Phase 3
- Empasiprubartargenx · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- XembifyGrifols Therapeutics LLC · Phase 3
- HYQVIATakeda · Phase 3
Coming up2
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2027 | A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy | |
| Phase 3Recruiting | 31 Aug 2028 | A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma | |
| Phase 3Completed | 28 Mar 2022 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency | |
| Phase 2Completed | 25 Aug 2021 | Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026